The drug in question, Rituxan, is what we call an immunotherapeutic monoclonal antibody which has a unique ability to bind itself to cancer cells without the toxic effects that are often associated with other cancer treating drugs.
Le médicament en question, le Rituxan, est un anticorps monoclonal imunothérapeutique qui a la caractéristique unique de se souder aux cellules cancéreuses sans provoquer les effets secondaires toxiques qui sont souvent associés aux médicaments anticancéreux.
